

Reporting Research & Evaluating Studies

Q. Eileen Wafford, Research Librarian Galter Health Sciences Library & Learning Center q-wafford@northwestern.edu Last Updated March 2019

M Northwestern Medicine® Feinberg School of Medicine

About this Class

- Overview of key concepts
- **■** Reporting guidelines for authors
- Checklists for reviewers
- Additional resources




Reporting Research and Evaluating Studies Guide

galter.northwestern.edu > Research Services > GalterGuides > Evidence-Based Practice > Reporting Research and Evaluating Studies

M Northwestern Medicine*
Feinberg School of Medicine

Writing & Research Resources at NU The Writing Place CLIMB Written Communication Resources Writing and Terminology GalterList Northwestern University Office for Research Feinberg Research Office Biostatistics Collaboration Center (BCC)



Impact of Poor Reporting

- Delayed publication
- Biased results and misleading information published
- **Adverse effects on researchers, clinicians, and patients**

M Northwestern Medicine* Feinberg School of Medicine 5

What to Report

- Methodology
- Results
- Potential conflicts

M Northwestern Medicine®

Reporting Methods

The PICO framework is a great tool for identifying key methodological information



Patient/Population/Problem

Important characteristics – Inclusion/exclusion criteria – Sample size – Recruitment and assignment – Address confounders



Intervention or Exposure

Explicit mention of the intervention or exposure. This can be a treatment, procedure, diagnostic test, prognostic factors



Comparator

Main alternative to compare with the intervention. This is often optional and can be a placebo.



Outcome

Description of what you hope to accomplish, measure, improve or affect. Mention primary and secondary outcomes.

7

What to Report Results

Estimates

Strength of the associations or relationships

Relative risk (RR), Odds ratio (OR)

Inferences

Demonstrate statistical significance

Confidence interval, P-value Type I error, Type II error

Adjustments

Account for differences between groups

Stratification, Multivariate models, Logistic regression, Linear regression

M Northwestern Medicine's Feinberg School of Medicine

Bias Identify and address bias Pre **Post During** Bias in Selection **Performance** Outcome **Allocation** reporting Interviewer Research **Detection Attrition** Citation **Publication** M Northwestern Medicine*

What to Report Potential Conflicts Conflicts of Interests Acknowledge potential conflicts Disclosure statements Funding sources MNorthwestern Medicine* Fericher School of Medicine*

Reporting Guidelines

- Recommend the minimum set of information
- Specific to a study design
- **⊜** Checklists, flow diagrams, or structured text
- Usually include "explanation and elaboration"

M Northwestern Medicine® Feinberg School of Medicine 11

Reporting Guidelines

- Based on evidence
- Developed by consensus
- **■** Provide guidance not requirements
- **■** Remember cite your reporting guideline!

M Northwestern Medicine®

Reporting Guidelines Benefits

- **■** Improve accuracy and transparency of research
- Promote replication by researchers
- **■** Improve efficiency of literature searching
- **■** Enable readers to critically appraise the study
- **■** Help clinicians apply research to clinical decision-making

M Northwestern Medicine®

13

Reporting Guidelines

GENERIC & SPECIFIC

M Northwestern Medicine* Feinberg School of Medicine

Reporting Guidelines "Generic"

- Generally applicable
- Include key methodology features

Critical Appraisal Resources Guide

galter.northwestern.edu > Explore Galter > Guides > Evidence-Based Practice > Critical Appraisal Resources

https://galter.northwestern.edu/guides-and-tutorials/critical-appraisal-resources?category=28

M Northwestern Medicine®

CONSORT STROBE

"Generic" Reporting Guidelines

PRISMA SQUIRE

15

CONSORT

Consolidated Standards of Reporting Trials

were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons Sample size 7a How sample size was determined 7b When applicable, explanation of any interim analyses and stopping guidelines	Section/Topic	Item No	Checklist item	Reported on page No
Introduction Background and Objectives 2b Specific detectors or hypotheses Scientific background and explanation of rationale Objectives 2b Specific detectors or hypotheses Methods Trial design 3a Inspection of trial design (such as parallel, factorial) including allocation ratio billion or participants 4a Elipibility criteria for participants 4b Settings and locations where the data were collected Interventions 5 The interventions for each group with sufficient defails to allow replication, including how and when they were actually administered Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were accessed were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explanation of any interim analyses and stopping guidelines Randomisation: Sequence 9a Method used to generate the random allocation sequence generation 9 Weithout set of implement the random allocation sequence describing any steps tisken to conceal the sequence guence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured underest), describing any steps tisken to conceal the sequence (such as suppured (such	Title and abstract			
Introduction Background and Objectives 2 b Specific dejectives or hypotheses Methods Trial design Sa Description of frail design (such as parallet, factoriat) including allocation ratio important changes to methods after trial commencement (such as eligibility criteria), with reasons Participants Sa Eligibility criteria for participants 40 Settings and locations where the data were collected Interventions 5 The interventions 5 The interventions 6 Settings and locations where the data were collected Cutcomes 6 Completely defined perspecified primary and secondary outcome measures, including how and when they were assets 5 Any changes to rist outcomes after the trial commenced, with reasons Sample size 7 How sample size was determined 7 When applicable, explanation of any interim analyses and stopping guidelines Randomisation. Sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation sequence 9 Method used to generate the random allocation s		1a	Identification as a randomised trial in the title	
Background and 2a Scientific background and explanation of rationale objectives 2b Specific objectives or hypotheses Methods Trist design 3a Description of trial design (such as parallel, factorial) including allocation ratio Important changes to methods after trial commencement (such as eligibility criteria properties). Participants 4a Eligibility criteria for participants 4b Settings and locations where the data were collected Interventions 5 The interventions for each group with sufficient defails to allow replication, including how and when they were actually administered Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explanation of any interim analyses and slopping guidelines Randomisation. Sequence 8a Method used to generate the random allocation sequence generation 9 Weichansin used to implement the random allocation sequence (such as separatily numbered containers), describing any steps tisken to conceal the sequence guence (such as segond)		1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	
Specific objectives or hypotheses	Introduction			
Methods Trisl design 3a Description of trial design (such as parallel, factorial) including allocation ratio Important changes to methods after trial commencement (such as eligibility criteria portant changes to methods after trial commencement (such as eligibility criteria), with reasons 4a Eligibility criteria for participants 5 The interventions 15 The interventions for each group with sufficient defails to allow replication, including how and when they were actually administered Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explanation of any interim analyses and slopping guidelines Randomisalion. Sequence 9a Method used to generate the random allocation sequence 9b Type of randomisation, details of any restriction (such as blocking and block size) Mechanism used to implement the random allocation sequence (such as segment) Mechanism used to implement the random allocation sequence (such as segment)	Background and	2a	Scientific background and explanation of rationale	
Trial design 3a Description of that idesign (such as parallet, flactorial) including allocation ratio	objectives	2b	Specific objectives or hypotheses	
Trial design 3a Description of that idesign (such as parallet, flactorial) including allocation ratio				
Begin Begi		20	Description of trial degrap (gueb as parallel, factorial) including allocation ratio	
Participants 4a Eliphility criteria for purticipants 4b Sattings and locations where the data were collected Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were accusally administered Curtomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Arry changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explaination of any interim analyses and stopping guidelines Randomisation: Sequence 8a Wethout used to generate the random allocation sequence (such as sequentially numbered containers), describing any steps tisken to conceal the sequence (such as seguentially numbered containers), describing any steps tisken to conceal the sequence (such as seguentially numbered containers),				
45 Settings and locations where the data were collected Interventions 5 and prough with sufficient details to allow replication, including how and when they were accually administered Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons Sample size 7 how sample size was determined 7b When applicable, explanation of any interim analyses and stopping guidelines Sequence 8 Method used to generate the random allocation sequence generation 8b Type of randomisation, details of any restriction (such as blocking and block size) Mochanism used to implement the random allocation sequence (such as seguentially numbered containers), describing any steps taken to conceal the sequence of the seguence of the seguration of the seguence of the seguration of the seguence of the seguration of the seg	Destinierente			
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered Corripotety defined pre-specified primary and secondary outcome measures, including how and when they were assessed by Amy changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explanation of any interim analyses and stopping guidelines Paradomisation: Sequence 8a Wethout used to generate the random allocation sequence generation 9b Type of randomisation, details of any restriction (such as blocking and block size) Michanism used to implement the random allocation sequence (such as segmentally numbered containers), describing any steps taken to conceal the sequence (such as segmentally numbered containers), describing any steps taken to conceal the sequence (such as segmentally numbered containers).	Participants			
actually administered Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed Any changes to trial outcomes after the trial commenced, with reasons Any changes is trial outcomes after the trial commenced, with reasons Any changes is trial outcomes after the trial commenced, with reasons Any changes is trial outcomes after the trial commenced, with reasons Any changes is trial outcomes after the trial outcomes adopting guidelines Anomalies in the second properties of the second properties and stopping guidelines Allocation 8 The second properties and second prop	Interventions			
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons 7b When applicable, explanation of any interim analyses and slopping guidelines 8 and secondary outcomes 8a (which are supplicable, explanation of any interim analyses and slopping guidelines 8 and secondary outcomes 8b Type of randomisation, details of any restriction (such as blocking and block size) 8b Type of randomisation, details of any restriction (such as blocking and block size) 8c Type of randomisation, details of any restriction (such as slopcing outcomes were signed of describing any steps tisten to conceal the sequence of the secondary outcomes were signed 8c. Type 1 and 1	IIIterveriuons	3		
were assessed by Any changes to frail outcomes after the frail commenced, with reasons Sample size 7a How sample size was determined 7b When applicable, explanation of any interim analyses and stopping guidelines Randomisation: Repulsor Be Whethou sed to generate the random allocation sequence generation By Type of randomisation, details of any restriction (such as blocking and block size) Mochanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Outcomes	6a		
Sample size 7a How sample size was determined 7b When applicable, explanation of any interim analyses and stopping guidelines Randomisation: Sequence 8 Method used to generate the random allocation sequence generation 8b Type of randomisation, details of any restriction (such as blocking and block size) Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence of uniforms were assigned	Odtoomoo	-		
Sample size 7a how sample size was determined 7b When applicable, explanation of any interim analyses and slopping guidelines Randomisation: Sequence 8 Method used to generate the random allocation sequence generation 8b Type of randomisation, details of any restriction (such as blocking and block size) Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps tisken to conceal the sequence (such as seguentially numbered containers),		6b	Any changes to trial outcomes after the trial commenced, with reasons	
Randomisation: Sequence generation Bb Type of randomisation, details of any restriction (such as blocking and block size) Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence of the segment	Sample size	7a		
Sequence 8a Method used to generate the random allocation sequence 9 Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned		7b	When applicable, explanation of any interim analyses and stopping guidelines	
generation 8b Type of randomisation; details of any restriction (such as blocking and block size) Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Randomisation:			
Allocation 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Sequence	8a	Method used to generate the random allocation sequence	
concealment describing any steps taken to conceal the sequence until interventions were assigned	generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	
	Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	
mechanism			describing any steps taken to conceal the sequence until interventions were assigned	
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions.	Implementation	10		

M Northwestern Medicine* Feinberg School of Medicine

STROBE

STrengthening the Reporting of OBservational studies

in Epidemiology

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
		participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and
		unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding

M Northwestern Medicine* Feinberg School of Medicine 17

PRISMA

Preferred Reporting Items for Systematic Reviews and

Meta-Analyses

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
METHODS		·	
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.	

M Northwestern Medicine* Feinberg School of Medicine

Reporting Guidelines "Specific"

- **■** Include greater degree of specificity
- Designed around a specific condition/field/intervention
- Used with relevant generic guideline

i.e., Reporting in implementation research of nurturing care interventions designed to promote early childhood development (ECD).

M Northwestern Medicine* Feinberg School of Medicine 19

Sources of Reporting Guidelines

- Equator Network
- For author pages
- Published studies
- Galter Guide

M Northwestern Medicine*




https://www.equator-network.org/

Consists of:

- Researchers
- Editors
- Peer reviewers
- Developers of reporting guidelines
- Research funding bodies
- Other collaborators

The EQUATOR mission is to achieve accurate, complete, and transparent reporting of all health research studies to support research reproducibility and usefulness.

M Northwestern Medicine*



Good reporting is not an optional extra: it is an essential component of doing good research

Vellore, 11 January 2010

Evaluating Published Studies Critical Appraisal

Critical appraisal is the process of carefully and systematically examining research evidence to judge its trustworthiness, its value and relevance in a particular context.

Mhaskar R, Emmanuel P, Mishra S, Patel S, Naik E, Kumar A. Critical appraisal skills are essential to informed decision-making. Indian Journal of Sexually Transmitted Diseases. 2009;30(2):112-119.

Evaluating Published Studies Critical Appraisal

Assess methodological soundness

- Does this study address a clearly focused question? Remember PICO
- Did the study use valid methods to address this question?
- Are the appropriate sample, assignment, and assessment points addressed?

Evaluate results and interpretations

- Are the results valid?
- Are the interpretations accurate?

25

Evaluating Published Studies Critical Appraisal

ldentify and assess bias

- Did the study use valid methods to address their question?
- Do the authors address potential sources of conflict?

Bias in Research

Pre

- Selection
- Allocation
 Detection

During

- Performance
- InterviewerAttrition

Post

- Outcome
- reporting
- · Citation
- · Publication

Evaluating Published Studies Critical Appraisal

Critically-Appraised
Topics [Evidence
Synthess and Guidelines)
Critically-Appraised Individual
Articles [Article Synopess]
Randomized Controlled Trials
(RCTs)
Cohort Studies
Case-Controlled Studies
Case Series / Reports

Background Information / Expert Opinion

Determine relevancy

- Is the study design appropriate for the research question?
 - Check out the Oxford CEBM Levels of Evidence
- Are the valid results of this study important?
- Are the results applicable to your patient, population, or problem?

27

Critical Appraisal Checklists

- Developed around a study design
- More concise with fewer checklist items
- Based on evidence
- Developed by consensus



Additional Resources

- Calculators
- Books and articles
- Guide

29

References

- Center, D. U. M. (2017, Mar 17, 2017). Asking the well built clinical question. Retrieved from http://guides.mclibrary.duke.edu/c.php?g=158201&p=1035584
- McGauran, N., Wieseler, B., Kreis, J., Schuler, Y. B., Kolsch, H., & Kaiser, T. (2010). Reporting bias in medical research a narrative review. Trials, 11, 37. doi:10.1186/1745-6215-11-37
- Medicine, C. f. E.-B. (2005). THERAPY STUDY: Are the results of the trial valid? (Internal Validity). University of Oxford. Retrieved from http://www.cebm.net/critical-appraisal/
- Mhaskar, R., Emmanuel, P., Mishra, S., Patel, S., Naik, E., & Kumar, A. (2009). Critical appraisal skills are essential to informed decision-making. Indian J Sex Transm Dis, 30(2), 112-119. doi:10.4103/0253-7184.62770
- Pannucci, C. J., & Wilkins, E. G. (2010). Identifying and avoiding bias in research. Plast Reconstr Surg, 126(2), 619-625. doi:10.1097/PRS.0b013e3181de24bc
- Richards, D. (2009). GRADING--levels of evidence. Evid Based Dent, 10(1), 24-25. doi:10.1038/sj.ebd.6400636
- Riegelman, R. K., & Ovid Technologies Inc. (2005). Studying a study and testing a test how to read the medical evidence Retrieved from
 - $\label{login} $$ $$ http://ezproxy.neu.edu/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=booktext&NEWS=N&DF=bookdb&AN=01223040/5th_Edition/2&XPATH=/PG(0) $$$
- Whitlock, R. P., Devereaux, P. J., Teoh, K. H., Lamy, A., Vincent, J., Pogue, J., . . . Investigators, S. (2015). Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet, 386(10000), 1243-1253. doi:10.1016/S0140-6736(15)00273-1
- Young, J. M., & Solomon, M. J. (2009). How to critically appraise an article. Nat Clin Pract Gastroenterol Hepatol, 6(2), 82-91. doi:10.1038/ncpgasthep1331

M Northwestern Medicine

